Vivus, Auxilium sign Canadian marketing deal


Vivus (VVUS) has licensed the exclusive rights to market its Stendra erectile-dysfunction drug in the U.S. and Canada to Auxilium Pharmaceuticals (AUXL).

Under the agreement, Vivus will receive as much as $300M in regulatory and sales milestones, including $30M upfront and $15M contingent upon a potential label amendment. Vivus will also receive royalties on any sales.

Auxilium expects to launch Stendra by the end of 2013.

Vivus shares +1.8% premarket. (PR)

This was corrected on 10/14/2013 at 03:45 PM.
From other sites
Comments (2)
  • phemale60
    , contributor
    Comments (3028) | Send Message
     
    Glad I bought more yesterday!!
    11 Oct 2013, 08:32 AM Reply Like
  • healthythoughts
    , contributor
    Comments (2988) | Send Message
     
    Wow! Glad you bought more, too....Good job! Probably see more action in coming months...
    12 Oct 2013, 06:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs